Call Me Anything but Thoughtless or Misguided in IBD Management

Crossmark: check for updates

Authors

  • Nicholas V. Costrini Gastroenterology Associates of Big Bend, Tallahassee, Florida, USA

DOI:

https://doi.org/10.17140/GOJ-4-129

Abstract

I read with interest the open access, original article, by S.K. Murthy, et al, Introduction of anti-tumor necrosis factor (TNF) therapy has not yielded expected declines in hospitalization and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study appearing in Gut 12 June 2019.1 It must first be stated that the authors are to be congratulated for the magnificent demonstration of the benefits of the Canadian healthcare system in terms of collection of healthcare data.

References

Murthy SK, Begum J, Bechamel EL, et al. Introduction of anti-TNF therapy has not yielded expected declines in hospitalization and intestinal resection rates in inflammatory bowel disease: A population-based interrupted time series study. Gut. 2019; 1-9. doi: 10.1136/gutjnl-2019-318440

Hanauer SB, Feagan BG, Lichtnestein GR, et al. Maintenance infliximab for Crohn’s Disease: The ACCENT I randomized trial. Lancet. 2002; 4: 1541-1549. doi: 10.1016/S0140-6736(02)08512-4

Sands, BE, Anderson FH, Bernstein CN, et al. Infliximab Main-tenance Therapy for Fistulizing Crohn’s Disease. N Engl J Med. 2004; 350: 876-885. doi: 10.1056/NEJMoa030815

Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s Disease: The CHARM trial. Gastroenterology. 2007; 132: 52- 65. doi: 10.1053/j.gastro.2006.11.041

Khanna R, Bressler B, Levesque BG, et al. Early combined im-munosuppression for the management of Crohn’s Disease (RE-ACT): A cluster randomized controlled trial. Lancet. 2015; 386: 1825-1834. doi: 10.1016/S0140-6736(15)00068-9

Rutgeerts P, VanAssche G, Sandorn WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn’s Letter to the Editor | Volume 4 | Number 1| disease: Data from the EXTEND trial. Gastroenterology. 2012; 142: 1102-1111. doi: 10.1053/j.gastro.2012.01.035

Colombel JF Panaccione r, Bossuyt P, et al. Effect of tight con-Submit your article to this journal | https://openventio.org/submit-manuscript/ Letter to the Editor | Volume 4 | Number 1| Costrini NV trol management on Crohn’s Disease (CALM): A multicenter, ran-domized, controlled phase 3 trial. Lancet. 2018; 390: 2779-2789. doi: 10.1016/S0140-6736(17)32641-7

Downloads

Published

2019-09-26

How to Cite

Nicholas V. Costrini. (2019). Call Me Anything but Thoughtless or Misguided in IBD Management. Gastro, 4(1), 4–6. https://doi.org/10.17140/GOJ-4-129

Issue

Vol. 4 No. 1 (2019): Volume 4 Issue 1 2019

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All content published in Gastro (GOJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.